Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KRYS
- Price
- 287.84
- Stock movement up
- +11.39 (4.12%)
- Company name
- Krystal Biotech Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 8.35B
- Ent value
- 8.06B
- Price/Sales
- 22.37
- Price/Book
- 7.34
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 41.96
- Forward P/E
- 34.28
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 84.81%
- 3 year return (CAGR)
- 55.37%
- 5 year return (CAGR)
- 31.67%
- 10 year return (CAGR)
- -
Last updated: 2026-03-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KRYS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 41.96 |
| Price to OCF | 47.37 |
| Price to FCF | 50.41 |
| Price to EBITDA | 48.76 |
| EV to EBITDA | 47.07 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 22.37 |
| Price to Book | 7.34 |
| EV to Sales | 21.59 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.00M |
| EPS (TTM) | 6.84 |
| FCF per share (TTM) | 6.31 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 389.13M |
| Gross profit (TTM) | 360.36M |
| Operating income (TTM) | 161.29M |
| Net income (TTM) | 204.83M |
| EPS (TTM) | 6.84 |
| EPS (1y forward) | 10.87 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.61% |
| Operating margin (TTM) | 41.45% |
| Profit margin (TTM) | 52.64% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 496.30M |
| Net receivables | 127.42M |
| Total current assets | 1.02B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 189.30M |
| Total assets | 1.33B |
| Accounts payable | 3.24M |
| Short/Current long term debt | 9.34M |
| Total current liabilities | 102.94M |
| Total liabilities | 114.23M |
| Shareholder's equity | 1.22B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 200.87M |
| Capital expenditures (TTM) | 11.95M |
| Free cash flow (TTM) | 188.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 16.80% |
| Return on Assets | 15.36% |
| Return on Invested Capital | 16.77% |
| Cash Return on Invested Capital | 15.47% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 289.00 |
| Daily high | 298.30 |
| Daily low | 270.71 |
| Daily Volume | 843K |
| All-time high | 291.93 |
| 1y analyst estimate | 313.22 |
| Beta | 0.51 |
| EPS (TTM) | 6.84 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 2 Mar 2026 |
Downside potential
Loading...
Downside potential data
| KRYS | S&P500 | |
| Current price drop from All-time high | -1.40% | -1.82% |
| Highest price drop | -53.42% | -56.47% |
| Date of highest drop | 26 Nov 2021 | 9 Mar 2009 |
| Avg drop from high | -16.46% | -10.84% |
| Avg time to new high | 17 days | 12 days |
| Max time to new high | 344 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
8.35B
Marketcap category
Mid-cap
Description
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Employees
295
Website
Investor relations
-
SEC filings
CEO
Krish S. Krishnan
Country
USA
City
Pittsburgh
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page